People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

The poisonous flower yellow oleander is showing up in diet supplements. There are now warnings for 22 dietary supplements ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The FDA claimed these clinics were plying patients with an illegal drug derived from their stem cells. A federal court agrees ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The panel agreed with the FDA that the treatment in which a patient's tissue is processed doesn't fall under the same ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The U.S. Food and Drug Administration reports a pet food company is voluntarily withdrawing some of their beef and chicken ...

Getting your yearly flu vaccine is essential to prevent illness during cold and flu season. But if you’re not a fan of ...